Phase 1 Parkinson's Disease Trial, Recruiting NCT07604116 Sponsor: Synusight Biotech (Shanghai) Co., Ltd. Condition: Parkinson's Disease
Back to Parkinsons Disease

Phase 1 Parkinson's Disease Trial, Recruiting

NCT07604116
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 40 years or older, of any gender
  • People who have signed the consent form approved by the ethics committee
  • People whose organs (such as liver and kidneys) are functioning at an adequate level
  • People who are willing and able to use appropriate contraception methods during the study
  • People who are willing to follow all study procedures
  • For healthy volunteers: People who are in good general health with no history of movement or thinking/memory disorders
  • For people with MSA (Multiple System Atrophy): People formally diagnosed with MSA according to recognised 2022 diagnostic guidelines, and whose MSA treatment (if any) has remained unchanged for at least 4 weeks with no changes planned soon
  • For people with PD (Parkinson's Disease): People formally diagnosed with PD according to recognised 2015 diagnostic guidelines, and whose PD treatment (if any) has remained unchanged for at least 4 weeks with no changes planned soon

Who may not be able to join:

  • People who are pregnant or currently breastfeeding
  • People with a history of other serious neurological conditions
  • People with a serious or poorly controlled ongoing medical condition
  • People with an active hepatitis B, hepatitis C, or HIV infection
  • People who have misused drugs or alcohol within the past year
  • People with a known allergy to the study drug
  • People who are unable to tolerate PET/CT or MRI scans (for example, due to claustrophobia)
  • People who have taken part in another interventional clinical trial within the past 30 days
  • People whose radiation exposure from medical procedures has already reached 50 mSv or more in the current year
  • People who have previously received any treatment specifically targeting a protein called alpha-synuclein (α-Syn)
  • People with any other condition the trial site considers makes participation unsuitable (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +86 021-52888163

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Synusight Biotech (Shanghai) Co., Ltd.
Registry
ClinicalTrials.gov
Start date
15 June 2026
Est. completion
1 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Incidence of Adverse Events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov